Showing 1111-1120 of 1781 results for "".
- Vitiligo: From Obscurity to Spotlight – Advancing Care with New Therapies and AIhttps://reachmd.com/news/vitiligo-from-obscurity-to-spotlight-advancing-care-with-new-therapies-and-ai/2468275/Over the past decade, vitiligo has transitioned from relative obscurity to become a focal point in dermatological research and clinical practice. This Research Topic aims to explore the recent surge in vitiligo-related studies, offering a comprehensive overview of cu
- Wearable Chest Sleep Apnea Test Receives FDA Clearancehttps://reachmd.com/news/wearable-chest-sleep-apnea-test-receives-fda-clearance/2467887/The Food and Drug Administration (FDA) has granted 510(k) clearance to SANSA (Huxley Medical, Atlanta, GA), a sleep apnea patch that is worn on the chest. SANSA is an at-home, single-point-of-contact diagnostic device that does not require additional attachments such as
- Managing Screen Time Without Banning Technologyhttps://reachmd.com/news/managing-screen-time-without-banning-technology/2467823/During the pandemic Jan Plass learned firsthand how nuanced the discussion around kids and screen time has to be. At one point, he became upset with his teenage children about how much time they were spending in front of screens.“So I go into their rooms ready to tell the
- Widespread Practice Among Athletes Harms Both Performance and Healthhttps://reachmd.com/news/widespread-practice-among-athletes-harms-both-performance-and-health/2467380/Whether selected to swim, row or run in the Olympics, or gearing up to ride in the Tour de France, achieving the 'right' weight has been a focal point of many elite athletes for decades. It could be to look lean and mean in a swimsuit or jersey, or to qualify for a certain weight cate
- Scientists: Obesity Battle Extends Beyond Lifestyle Changeshttps://reachmd.com/news/scientists-obesity-battle-extends-beyond-lifestyle-changes/2463215/Anti-obesity drugs such as Ozempic were the "breakthrough of the year" in 2023, according to the AAAS journal Science. Overweight and obesity rates are rising worldwide, with several Latin American countries in the forefront. Estimates for 2020 pointed to a global obesity rate of 1
- Study Lays the Basis for New Knowledge on Gastrointestinal Diseaseshttps://reachmd.com/news/study-lays-the-basis-for-new-knowledge-on-gastrointestinal-diseases/2462699/The transition from the esophagus to the stomach is a delicate region from a medical point of view, often associated with pathological disorders leading to cancer. An international research team has now gained new insights into this region. These pave the way for new prevention and treat
- Low Iron Levels Resulting from Infection Could Be Key Trigger of Long COVIDhttps://reachmd.com/news/low-iron-levels-resulting-from-infection-could-be-key-trigger-of-long-covid/2457438/The discovery not only points to possible ways to prevent or treat the condition, but could help explain why symptoms similar to those of long COVID are also commonly seen in a number of post-viral conditions and chronic inflammation. Although estimates are highly variable, as m
- Four IBS Diet Strategies Show Distinct Profiles In Reviewhttps://reachmd.com/news/four-ibs-diet-strategies-show-distinct-profiles-in-review/2487297/Key Takeaways Low FODMAP interventions showed relatively consistent short-term response, but pooled analysis did not show a significant advantage over other dietary approaches. Mediterranean-based interventions appeared promising at longer follow-up in
- Ketogenic Diet Trial in Treatment-Resistant Depressionhttps://reachmd.com/news/ketogenic-diet-trial-in-treatment-resistant-depression/2486866/Key Takeaways The ketogenic diet was associated with a modestly greater reduction in depressive symptoms at 6 weeks, but there was no significant between-group difference at 12 weeks. Most secondary outcomes were similar between groups, although anxiet
- Gut Microbiome Patterns Linked to IBS-D Response to Rifaximin, Diethttps://reachmd.com/news/gut-microbiome-patterns-linked-to-ibs-d-response-to-rifaximin-diet/2486812/Key Takeaways Five-week decreases in abdominal pain and bloating were comparable after rifaximin and low FODMAP diet counseling. Baseline microbiome features differed among low FODMAP responders, rifaximin responders, and patients who did not respond t